Lytix Biopharma AS (DE:6BG) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lytix Biopharma’s lead drug, LTX-315, is undergoing a phase II study by licensing partner Verrica Pharmaceuticals for treatment of basal cell carcinoma (BCC), the most common cancer globally. Preliminary top-line results are expected to be announced soon, coinciding with Verrica’s Q2 financial report. Lytix is also progressing with studies targeting skin melanoma at Oslo University Hospital.
For further insights into DE:6BG stock, check out TipRanks’ Stock Analysis page.